We are live on ! Find out more
CFO

Callan Family Office Portfolio holdings

AUM $4.41B
1-Year Est. Return 26.21%
This Fund
S&P 500
This Quarter Est. Return
+4.14%
1 Year Est. Return
+26.21%
3 Year Est. Return
+68.96%
5 Year Est. Return
10 Year Est. Return
AUM
$4.65B
AUM Growth
+$1.52B
Cap. Flow
+$1.42B
Cap. Flow %
30.5%
Top 10 Hldgs %
26.25%
Holding
1,130
New
282
Increased
733
Reduced
76
Closed
19

Sector Composition

Rank Sector Weight
1 Technology 22.93%
2 Financials 13.36%
3 Healthcare 9.15%
4 Industrials 7.57%
5 Consumer Discretionary 7.57%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
COST icon
51
Costco
COST
$420B
$16.4M 0.35%
19,070
+1,120
+6% +$1.01M
ORCL icon
52
Oracle
ORCL
$423B
$15.7M 0.34%
80,577
+23,353
+41% +$5.56M
ITOT icon
53
iShares Core S&P Total US Stock Market ETF
ITOT
$97.8B
$15.3M 0.33%
103,148
-1,679
-2% -$248K
ABT icon
54
Abbott
ABT
$187B
$15.1M 0.32%
120,588
+27,924
+30% +$3.56M
MU icon
55
Micron Technology
MU
$991B
$14.7M 0.32%
51,382
+17,476
+52% +$4.01M
NOW icon
56
ServiceNow
NOW
$129B
$14.5M 0.31%
94,763
+24,993
+36% +$4.29M
NVS icon
57
Novartis
NVS
$297B
$14.5M 0.31%
104,847
+16,872
+19% +$2.21M
VEA icon
58
Vanguard FTSE Developed Markets ETF
VEA
$237B
$14.2M 0.31%
227,480
+134,730
+145% +$8.25M
MRSH
59
Marsh
MRSH
$91.5B
$14.1M 0.3%
76,243
+13,214
+21% +$2.47M
BNY
60
Bank of New York Mellon
BNY
$107B
$14M 0.3%
120,975
+12,395
+11% +$1.37M
GSK icon
61
GSK
GSK
$106B
$14M 0.3%
285,929
+66,376
+30% +$3.1M
JNJ icon
62
Johnson & Johnson
JNJ
$625B
$13.9M 0.3%
67,398
+12,878
+24% +$2.55M
INTU icon
63
Intuit
INTU
$89B
$13.9M 0.3%
21,003
+5,889
+39% +$3.89M
CVX icon
64
Chevron
CVX
$366B
$13.5M 0.29%
88,524
+20,015
+29% +$3.05M
APP icon
65
Applovin
APP
$116B
$13.5M 0.29%
19,970
+9,410
+89% +$5.93M
ABBV icon
66
AbbVie
ABBV
$435B
$13.3M 0.29%
58,398
+17,044
+41% +$3.88M
ACWX icon
67
iShares MSCI ACWI ex US ETF
ACWX
$11.9B
$13.3M 0.28%
197,582
+150,616
+321% +$9.98M
VXUS icon
68
Vanguard Total International Stock ETF
VXUS
$163B
$13.1M 0.28%
173,360
+31,569
+22% +$2.36M
GILD icon
69
Gilead Sciences
GILD
$165B
$13M 0.28%
105,870
+17,592
+20% +$2.14M
AMD icon
70
Advanced Micro Devices
AMD
$789B
$12.8M 0.27%
59,634
+22,961
+63% +$5.16M
CVS icon
71
CVS Health
CVS
$122B
$12.3M 0.26%
155,304
+19,988
+15% +$1.58M
VWO icon
72
Vanguard FTSE Emerging Markets ETF
VWO
$126B
$12.3M 0.26%
228,175
+35,152
+18% +$1.91M
FDX icon
73
FedEx
FDX
$75.4B
$12.2M 0.26%
42,149
+4,318
+11% +$1.13M
XOM icon
74
ExxonMobil
XOM
$634B
$12.1M 0.26%
100,892
+24,214
+32% +$2.81M
AZN icon
75
AstraZeneca
AZN
$250B
$11.9M 0.26%
64,567
+43,227
+203% +$7.58M

Similar funds

Callan Family Office's Q4 2025 Portfolio in Review

As of Q4 2025, Callan Family Office held 1,130 positions worth $4.65B, up 48% from $3.14B the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Callan Family Office deployed $1.42B of net new capital in Q4 2025, opening 282 new positions and adding to 733 existing holdings. Its largest new stake was Vanguard Russell 3000 ETF: 228,815 shares worth $68.7M.

By sector, the portfolio is most concentrated in Technology at 23% of assets, down from 25% a quarter earlier, followed by Financials and Healthcare.

On the sell side, the largest reduction was Fiserv Inc, an estimated $3.75M trimmed.

  • Callan Family Office's largest Q4 2025 buy was Vanguard Russell 3000 ETF: 228,815 shares worth $68.7M.
  • Callan Family Office added most to Vanguard S&P 500 ETF in Q4 2025, an estimated $109M increase.
  • Callan Family Office's biggest Q4 2025 reduction was Fiserv Inc, cutting an estimated $3.75M.
  • Callan Family Office fully exited HubSpot in Q4 2025, selling an estimated $1.16M.
  • Callan Family Office's ten largest holdings make up 26% of its $4.65B portfolio in Q4 2025.
  • Callan Family Office opened 282 new positions and closed 19 in Q4 2025.
  • Callan Family Office's portfolio value rose 48% quarter-over-quarter to $4.65B.

Based on Callan Family Office's 13F filing for Q4 2025, filed 12 Feb 2026.